Pricing
  1. JP-listed companies
  2. TAIKO PHARMACEUTICAL CO., LTD.
  3. Financials
  4. Earnings per share

TAIKO PHARMACEUTICAL CO., LTD. (4574)

Market cap
¥15.4B
P/E ratio
27.8x
Makes over-the-counter medicines like Seirogan and Cleverin infection control products, serving consumers and institutions across Japan and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEarnings per share (JPY)YoY (%)
Dec 31, 202518.4+2.68%
Dec 31, 202417.9-123.48%
Dec 31, 2023-76.2-32.08%
Dec 31, 2022-112.3-49.09%
Dec 31, 2021-220.5-347.28%
Dec 31, 202089.2+54.91%
Mar 31, 202057.6-41.84%
Mar 31, 201999+27.93%
Mar 31, 201877.4+1.22%
Mar 31, 201776.5+17.20%
Mar 31, 201665.2-53.05%
Mar 31, 2015138.9+2.20%
Mar 31, 2014135.9+67.19%
Mar 31, 201381.3+118.40%
Mar 31, 201237.2

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat